Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 Single-Arm QTc Evaluation of Gemtuzumab Ozogamicin in Relapsed/Refractory CD33-Positive AML
2018-002619-89Phase 4Completed
- Sponsor
- Pfizer
- Start
- Dec 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by Pfizer. Primary endpoint: Maximum change from baseline in corrected QT interval (QTc). Started Dec 2018; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2018-002619-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002619-89.